---
document_datetime: 2025-12-18 15:22:59
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/puregon-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: puregon-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.897693
conversion_datetime: 2025-12-23 06:19:54.273152
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Puregon

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I.7 Deletion of: - C.I.7.b a strength - | 18/12/2025                          |                                             | SmPC,                            |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000316030                     | Accepted C.I.7.b - to delete the 150 IU /0.18 mL strength from the Puregon marketing authorisation (EU/1/96/008/040). The MAH took the opportunity to update the contact details of the list of local representatives in section 6 of the Package Leaflet for the following countries: Czech Republic, Denmark, Norway, Poland, Iceland, and to delete UK (NI).                                                                                                                                                           |            |     | Labelling and PL   |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------|
| Variation type IA / EMA/VR/0000286664 | A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted | 30/10/2025 |     | Annex II           |
| Variation type IB / EMA/VR/0000287074 | B.III.2 Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - B.III.2.z Other changes - Accepted                                                                                                                                                                                                                                                                                                                                                                                            | 07/08/2025 | N/A |                    |
| Variation type IB / EMA/VR/0000268877 | B.I.b.2 Change in test procedure for active substance or starting                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 30/05/2025 | N/A |                    |

<div style=\"page-break-after: always\"></div>

|                                       | material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted                                                                                                                                                                                                                                                                                                                                                   |            |     |                   |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|
| Variation type IA /                   | A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted                                                                                                                                                                            | 08/04/2025 | N/A | EMA/VR/0000263943 |
| Variation type IB / EMA/VR/0000246528 | This was an application for a group of variations. B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted | 25/03/2025 | N/A |                   |

<div style=\"page-break-after: always\"></div>

| Variation type IA / EMA/VR/0000249097   | B.II.e.7 Change in supplier of packaging components or devices (when mentioned in the dossier) - B.II.e.7.a Deletion of a supplier - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 12/02/2025   | N/A   |                   |
|-----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------------|
| Variation type IB /                     | B.II. FINISHED PRODUCT - B.II.z To update Module 3.2.A.1 for a biotech medicinal product - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 07/01/2025   | N/A   | EMA/VR/0000240854 |
| Variation type II /                     | This was an application for a group of variations. B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.d Substantial change to or replacement of a biological/ immunological/ immunochemical test method or a method using a biological reagent for a biological active substance - Accepted A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, | 19/12/2024   |       | EMA/VR/0000224916 |

<div style=\"page-break-after: always\"></div>

| dossier)* - Accepted   |
|------------------------|